Reverse total shoulder arthroplasty (RTSA) using trabecular metal (TM)-backed glenoid implants has been introduced with the aim to increase implant survival. Only short-term reports on the outcomes of TM-RTSA have been published to date. We aim to present the seven-year survival of TM-backed glenoid implants along with minimum five-year clinical and radiological outcomes. All consecutive elective RTSAs performed at a single centre between November 2008 and October 2014 were reviewed. Patients who had primary TM-RTSA for rotator cuff arthropathy and osteoarthritis with deficient cuff were included. A total of 190 shoulders in 168 patients (41 male, 127 female) were identified for inclusion at a mean of 7.27 years (SD 1.4) from surgery. The primary outcome was survival of the implant with all-cause revision and aseptic glenoid loosening as endpoints. Secondary outcomes were clinical, radiological, and patient-related outcomes with a five-year minimum follow-up.Aims
Methods
Average time between re-scopes was 16 months (range 0 to 3.5 years). The numbers of patients requiring repeat knee arthroscopy for similar clinical problems were 16 out of 695 patients (2.3%). During repeat arthroscopies, 10/16 (62%) required procedures on meniscus, 4/16 (25%) for osteochondral lesions 2 patients had same diagnosis as ACL tears. 90% of partial meniscectomies were repeated on the posterior horn of both medial and lateral meniscus, and 20% required trimming of body of the meniscus.